US: Trump Administration Partially Reschedules Cannabis Products

Cannabis Campaigners' Guide News Database result:

After you have finished reading this article you can click here to go back.

Fajar Ramadhan

Asatu News

Thursday 30 Apr 2026

Acting Attorney General Todd Blanche signed a federal order last week to partially reschedule cannabis, moving specific medical and FDA-approved products from Schedule I to Schedule III. As reported by The Guardian, the policy shift maintains strict federal controls while recognizing certain marijuana-related products as having accepted medical use.

The reclassification shifts qualifying substances into a category that includes regulated drugs like ketamine and Tylenol with codeine. However, the order specifically excludes adult-use or recreational cannabis, which remains under the most restrictive federal drug classification reserved for substances with no accepted medical application.

Cat Packer, director of drug markets and legal regulation at the Drug Policy Alliance, noted that the change does not represent a wholesale shift in federal marijuana policy.

"While some marijuana-related products are no longer being treated as schedule I, it’s not accurate to say marijuana has been broadly rescheduled – this is partial rescheduling, at best," said Cat Packer, director of drug markets and legal regulation at the Drug Policy Alliance.

Packer expressed concern regarding how the order handles future pharmaceutical developments in the industry.

"More concerning, it appears to predetermine the scheduling outcome for future FDA-approved drugs containing marijuana without a full, evidence-based risk evaluation," Packer added.

The administration cited the 1961 Single Convention on Narcotic Drugs to justify the bifurcated approach, arguing the treaty requires limits on cannabis production for non-scientific purposes.

"There’s an ongoing debate here," Packer said, "Some would argue that, given the federal government’s posture toward state legalization, the US is already functionally out of alignment with the treaty – similar to how Canada has approached legalization."

Industry experts suggest the move has complicated the regulatory landscape for businesses operating under state licenses.

"The administration’s recent announcement explained the bifurcation [between medical and other types of cannabis] was in part for an expedited, legally compliant pathway – but in practice, it’s made an already complex process more confusing," Packer said.

https://www.asatunews.co.id/en/cannabis-partial-rescheduling-trump-administration

After you have finished reading this article you can click here to go back.



This page was created by the Cannabis Campaigners' Guide.

Feel free to link to this page!